In conclusion, the combination of ribociclib with gemcitabine showed synergistic activity in certain tumor types in preclinical cell studies but may have antagonistic activity in others based on specific circumstances such as tumor type, the sequencing pattern of chemotherapy and targeted therapies and Rb status. Here, RB1 is linked to neoplasm.